CA
NZ
UK
AU
IND
US
● Rockwell Medical reported second-quarter 2026 net sales of about $17.8 million, up about 11% year over year, driven by new customers in the Western U.S.
● iRhythm reported second-quarter 2026Revenueof about $224.2 million, up about 20.1% year over year, with grossMarginimproving to about 72.8%.
● KORU Medical reported second-quarter 2026 net revenues of about $12.0 million, up about 18.2% year over year, with international coreRevenueup about 59.1%.
● Sera Prognostics reported minimalRevenuein its second-quarter 2026 results, reflecting its early commercial stage.
● LENSAR reported recordRevenueand returned to profitability in its second-quarter 2026 results, driven by strongDemandfor its ALLY cataract-surgery system.
● Caris reported record second-quarter 2026Revenueof about $263.7 million, up about 45% year over year, with record test volume.
● Collegium reported second-quarter 2026Revenueof about $199.9 million, with its ADHD portfolio surging.
● Citius reported LYMPHIR productRevenueof about $1.49 million in its fiscal third-quarter 2026 results, with the product now available at 44 oncology centers.
● GeneDx reported second-quarter 2026Revenueof about $114.4 million, up 11% year over year, with record test volume.
● Moleculin reported a second-quarter 2026 net loss of about $7.6 million and highlighted encouraging interim data from its pivotal MIRACLE trial in AML.
Please wait processing your request...